Faricimab (Genentech) offered non-inferior vision gains given at intervals of up to 4 months compared to aflibercept given every 2 months in patients with wet age-related macular degeneration (nAMD) or diabetic macular edema (DME), according to a press release.
In the four pphase 3 studies (the YOSEMITE and RHINE studies in DME and the TENAYA and LUCERNE studies in nAMD) faricimab was generally well-tolerated.
“These faricimab data offer the promise of a new treatment for two common causes of blindness, diabetic macular edema and neovascular age-related macular degeneration,” Jeffrey Heier, MD, Director of Retinal Research at Ophthalmic Consultants of Boston in Boston, said in a Genentech press release. “Faricimab’s potential to extend time between treatments may benefit those patients who struggle to keep up with the regular physician visits and eye injections needed to preserve their vision.”
Read the full press release here.
Related Content
